- Home
- CEF vs TFX Comparison
CEF vs TFX Comparison
Compare CEF & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEF
- TFX
- Stock Information
- Founded
- CEF N/A
- TFX 1943
- Country
- CEF
- TFX United States
- Employees
- CEF N/A
- TFX N/A
- Industry
- CEF
- TFX Medical/Dental Instruments
- Sector
- CEF
- TFX Health Care
- Exchange
- CEF NYSE
- TFX Nasdaq
- Market Cap
- CEF 5.4B
- TFX 5.3B
- IPO Year
- CEF N/A
- TFX N/A
- Fundamental
- Price
- CEF $29.06
- TFX $122.54
- Analyst Decision
- CEF
- TFX Hold
- Analyst Count
- CEF 0
- TFX 10
- Target Price
- CEF N/A
- TFX $176.50
- AVG Volume (30 Days)
- CEF N/A
- TFX 495.0K
- Earning Date
- CEF N/A
- TFX 05-01-2025
- Dividend Yield
- CEF N/A
- TFX 1.11%
- EPS Growth
- CEF N/A
- TFX N/A
- EPS
- CEF N/A
- TFX 3.20
- Revenue
- CEF N/A
- TFX $3,010,144,000.00
- Revenue This Year
- CEF N/A
- TFX $2.88
- Revenue Next Year
- CEF N/A
- TFX $4.85
- P/E Ratio
- CEF N/A
- TFX $38.19
- Revenue Growth
- CEF N/A
- TFX 0.29
- 52 Week Low
- CEF N/A
- TFX $119.08
- 52 Week High
- CEF N/A
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- CEF 51.70
- TFX 40.16
- Support Level
- CEF $28.98
- TFX $119.08
- Resistance Level
- CEF $29.36
- TFX $123.33
- Average True Range (ATR)
- CEF 0.28
- TFX 2.80
- MACD
- CEF 0.00
- TFX -0.06
- Stochastic Oscillator
- CEF 64.11
- TFX 14.58
About CEF SPROTT PHYSICAL GOLD AND SILVER TR
Sprott Physical Gold and Silver Trust is a closed end mutual fund trust. The trust invests and holds all of its assets in physical gold and silver bullion and seeks to provide a secure, convenient and exchange-traded investment alternative for investors interested in holding physical bullion without the inconvenience that is typical of direct investment.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.